Deconstructing Noncovalent Kelch-like ECH-Associated Protein 1 (Keap1) Inhibitors into Fragments to Reconstruct New Potent Compounds.
Jakob S PallesenDilip NarayananKim T TranSara M Ø SolbakGiuseppe MarsegliaLouis M E SørensenLars J HøjFederico MunafòRosa M C CarmonaAnthony D GarciaHaritha L DesuRoberta BrambillaTommy N JohansenGrzegorz M PopowiczMichael SattlerMichael GajhedeAnders BachPublished in: Journal of medicinal chemistry (2021)
Targeting the protein-protein interaction (PPI) between nuclear factor erythroid 2-related factor 2 (Nrf2) and Kelch-like ECH-associated protein 1 (Keap1) is a potential therapeutic strategy to control diseases involving oxidative stress. Here, six classes of known small-molecule Keap1-Nrf2 PPI inhibitors were dissected into 77 fragments in a fragment-based deconstruction reconstruction (FBDR) study and tested in four orthogonal assays. This gave 17 fragment hits of which six were shown by X-ray crystallography to bind in the Keap1 Kelch binding pocket. Two hits were merged into compound 8 with a 220-380-fold stronger affinity (Ki = 16 μM) relative to the parent fragments. Systematic optimization resulted in several novel analogues with Ki values of 0.04-0.5 μM, binding modes determined by X-ray crystallography, and enhanced microsomal stability. This demonstrates how FBDR can be used to find new fragment hits, elucidate important ligand-protein interactions, and identify new potent inhibitors of the Keap1-Nrf2 PPI.
Keyphrases
- protein protein
- small molecule
- oxidative stress
- nuclear factor
- toll like receptor
- high resolution
- ischemia reperfusion injury
- neoadjuvant chemotherapy
- dna damage
- induced apoptosis
- anti inflammatory
- diabetic rats
- molecular docking
- magnetic resonance imaging
- radiation therapy
- inflammatory response
- electron microscopy
- immune response
- squamous cell carcinoma
- magnetic resonance
- contrast enhanced
- lymph node